Publication Name	World Journal of Gastroenterology
Manuscript ID	15266
Country	Belgium

Received	2014-11-18 16:59
Peer-Review Started	2014-11-19 09:01
To Make the First Decision	2014-12-11 20:19
Return for Revision	2014-12-24 09:56
Revised	2015-01-07 04:11
Second Decision	2015-02-10 21:23
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-02-11 15:40
Articles in Press	2015-02-11 16:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-05 18:36
Publish the Manuscript Online	2015-04-27 16:22

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Konstantinos Papamichael and Severine Vermeire
Funding Agency and Grant Number
Corresponding Author	Konstantinos Papamichael, MD, PhD, FEBGH, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, Herestraat 49, 3000 Leuven, Belgium. konstantinos.papamichail@kuleuven.be
Key Words	Inflammatory bowel disease; Anti-tumour necrosis factor α therapy; Withdrawal; Remission; Infliximab
Core Tip	Anti-tumour necrosis factor α (anti-TNFα) therapy is an established treatment in inflammatory bowel disease. Although guidelines exist on initiation of anti-TNFα therapy in inflammatory bowel diseases, information on if, when, how and in whom therapy can be stopped is limited. This is nevertheless an important topic taking under consideration the cost and the possible adverse events associated with biological agents as well as the desire of patients to discontinue medication especially after a long maintained remission. Moreover, although drug discontinuation for reasons other than loss of response is very usual in real-life clinical practice, the optimal withdrawal strategy is still debated.
Publish Date	2015-04-27 16:22
Citation	Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778
URL	http://www.wjgnet.com/1007-9327/full/v21/i16/4773.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i16.4773

Full Article (PDF)	WJG-21-4773.pdf
Full Article (Word)	WJG-21-4773.doc
Manuscript File	15266-Review.doc
Answering Reviewers	15266-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15266-Conflict-of-interest statement.pdf
Copyright License Agreement	15266-Copyright assignment.pdf
Peer-review Report	15266-Peer-review(s).pdf
Scientific Misconduct Check	15266-Scientific misconduct check.pdf
Scientific Editor Work List	15266-Scientific editor work list.pdf